{"Previous": [0], "trials": [1], "showed": [2], "promising": [3], "antitumor": [4], "activity": [5], "and": [6, 55], "an": [7], "acceptable": [8], "safety": [9], "profile": [10], "associated": [11], "with": [12, 16, 36], "pembrolizumab": [13, 25], "in": [14, 52], "patients": [15, 35], "early": [17, 37], "triple-negative": [18, 38], "breast": [19, 39, 54], "cancer.": [20], "Whether": [21], "the": [22, 32, 53], "addition": [23], "of": [24, 34], "to": [26], "neoadjuvant": [27], "chemotherapy": [28], "would": [29], "significantly": [30], "increase": [31], "percentage": [33], "cancer": [40, 51], "who": [41], "have": [42], "a": [43], "pathological": [44], "complete": [45], "response": [46], "(defined": [47], "as": [48], "no": [49], "invasive": [50], "negative": [56], "nodes)": [57], "at": [58], "definitive": [59], "surgery": [60], "is": [61], "unclear.": [62]}